Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fremanezumab (Primary)
Indications Migraine
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Labrys Biologics; Teva Branded Pharmaceutical Products R&D; Teva Pharmaceutical Industries

23 May 2020 Results (n=2503) assessing relationships between differences in fremanezumab exposure resulting from monthly and quarterly dosing schedules and efficacy endpoints of the phase 2 and 3 clinical trials for fremanezumab by developing E-R models, published in the Headache.
18 Nov 2018 Results of post-hoc analyses assessing the efficacy of each dose during the first 3 weeks of treatment, published in the Headache.
17 Aug 2018 Results published in the Neurology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com